Pharmaceutical

Zealand and Roche strike $5.3bn obesity treatment deal

The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.

Mar 13, 2025 - 06:00
Zealand and Roche strike $5.3bn obesity treatment deal
The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.
Read the original article

Tags:

Previous Article

Vori Health secures $53m funding to support musculoskeletal care

Next Article

Canada and Alberta governments to invest in Entos R&D facility

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Could sickle cell someday be treated not with CRISPR, but with a pill?

STAT+: Could sickle cell someday be treated not with CR...

Dec 13, 2023

STAT+: U.S. Supreme Court declines bid by Teva to hear ‘skinny labeling’ case with implications for generic drug access

STAT+: U.S. Supreme Court declines bid by Teva to hear ...

May 15, 2023

‘We’re absolutely making it too hard’: The complexity of adult immunization delivery hinders vaccine uptake

‘We’re absolutely making it too hard’: The complexity o...

Oct 26, 2023